Dyne Therapeutics price target cut to $30 from $35 at RBC Capital
RBC Capital cut its Dyne Therapeutics price target to $30.00 per share from $35.00, according to a Benzinga ratings action roundup.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.